Nyxoah is trading 7.63% up in pre-market at $1.41 after investors continued to digest strong second-quarter results released on August 5.
- Global revenue reached €7.7 million, including €5.2 million from the U.S.; management reaffirmed 2026 revenue guidance of €36 million–€40 million and cited commercial momentum.
- The company secured $110 million in financing, supporting its U.S. commercialization ramp.
- Healthcare and U.S. futures are also higher, but company-specific earnings news remains the clearest catalyst.